ConductScience.org, home

Gene · 6612

SUMO3: small ubiquitin like modifier 3

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. SUMO3: small ubiquitin like modifier 3. Genes, record 6612. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6612

On this page

Gene

Symbol
SUMO3
HGNC
Name
small ubiquitin like modifier 3
HGNC
NCBI Gene ID
6612
NCBI Gene
HGNC ID
HGNC:11124
HGNC
Ensembl
ENSG00000184900
NCBI Gene
Aliases
SMT3A, SMT3H1, SUMO-3
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P55854Small ubiquitin-related modifier 31038Ensembl, GeneID, HGNC

Source UniProt

Patents50

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4805378 A12026-09-16100P55854Espacenet
JP 2026523341 A2026-07-14559P55854Espacenet
EP 4771137 A12026-07-0897P55854Espacenet
EP 4771157 A12026-07-0897P55854Espacenet
JP 2026108757 A2026-06-3034P55854Espacenet
US 12649003 B22026-06-09559P55854Espacenet
JP 2026510339 A2026-04-0297P55854Espacenet
EP 4713451 A22026-03-2597P55854Espacenet
EP 4713452 A22026-03-2597P55854Espacenet
US 12558437 B22026-02-24559P55854Espacenet

1 to 10 of 50

See all 50 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants917

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleSUMO3 papersNewest fiscal year
P30CA008748Cancer Center Support Grant72025
P30CA033572Cancer Center Support Grant72025
T32CA009110Training in Areas Fundamental to Cancer Research62025
R01CA073764FEN1-mediated Okazaki fragment maturation and its deficiency in cancer42025
ZIAHD001310Gene Regulation In The Immune System42025
P30CA093373Cancer Center Support Grant P3032025
P30DK050306Center for Molecular Studies in Digestive and Liver Diseases32025
R01CA256543Targeting Constitutively Active SUMO Modified Androgen Receptors in Endocrine Resistant Breast Cancer32025
R50CA211397Functional Analysis of Structure Specific Nucleases in Genome Stability and Cancers32025
ZIATR000018Drug Repurposing Screening for Rare and Neglected Diseases32025

1 to 10 of 917Source NIH's project files

See all 917 nih grants

Papers1,564

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
SEPT5 confers radioresistance by suppressing GSDME-dependent pyroptosis and antitumor immunity in non-small cell lung cancer.Int Immunopharmacol202642743876PubTator, text miningPubMed
SUMO3/RUNX1/AIRE/RCAN1 and DNMT3L/DYRK1A/Let-7c-5p/VEGF axes: immune dysregulation and genetic susceptibility as pulmonary risk factors in Down syndrome.3 Biotech202642245386PubTator, text miningPubMed
Denaturing SUMO Immunoprecipitation From Mitotic Cells.Bio Protoc202641971162PubTator, text miningPubMed
Small Ubiquitin-Like Modifier 3 Attenuates Lung Ischemia-Reperfusion Injury Progression by Inhibiting Endoplasmic Reticulum Stress through Heat Shock Protein 70.Am J Pathol202641881306PubTator, text miningPubMed
Inhibition of coronaviral exoribonuclease activity by TRIM-mediated SUMOylation.Proc Natl Acad Sci U S A202641871251PubTator, text miningPubMed
Cellular strategies for repairing trapped protein-DNA complexes.Front Pharmacol202641743125PubTator, text miningPubMed
SUMOylation is destined for regulatory T cell-related immune dysregulation.Cell Death Discov202641633969PubTator, text miningPubMed
SUMOylation machinery protein, PIAS4 role in breast cancer cell proliferation and drug sensitivity.Mol Biol Rep202641615552PubTator, text miningPubMed
A single-cell derived spheroid approach to dissect intratumoural heterogeneity in colorectal cancer: cell lines show changes in proteomes and therapeutic response to 5-FU.J Cancer Res Clin Oncol202641580526PubTator, text miningPubMed
Down-regulation of EHMT2 through irisin-mediated epigenetic modification promotes osteogenesis via promoting DLX3 transcription.Cell Commun Signal202641555399PubTator, text miningPubMed

1 to 10 of 1,564

See all 1,564 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/6612

GET https://conductscience.org/api/genes/v1/6612/patents?page=2